Novel approaches to the endocrine therapy of breast cancer

Formestane

“…[2,[33][34][35][36][37][38] Intramuscular formestane 50 mg/kg administered either daily or once every 2 weeks for up to 5 months caused tumour regression in approximately 90 to 100% of rats with chemically induced mammary tumours. [2,[33][34][35][36][37][38] Intramuscular formestane 50 mg/kg administered either daily or once every 2 weeks for up to 5 months caused tumour regression in approximately 90 to 100% of rats with chemically induced mammary tumours.…”

Formestane

“…[2,[33][34][35][36][37][38] Intramuscular formestane 50 mg/kg administered either daily or once every 2 weeks for up to 5 months caused tumour regression in approximately 90 to 100% of rats with chemically induced mammary tumours. [2,[33][34][35][36][37][38] Intramuscular formestane 50 mg/kg administered either daily or once every 2 weeks for up to 5 months caused tumour regression in approximately 90 to 100% of rats with chemically induced mammary tumours.…”

Induction of glioma cell death by 1,25 (OH)2 vitamin D3: Towards an endocrine therapy of brain tumors?

“…This knowledge gap, together with the absence of any curative treatment, has led to the development of other therapeutic approaches like immunotherapy (Merchant et al, 1992;Holladay et al, 1992;Trojan et al, 1993) and gene therapy (Culver et al, 1992). The endocrine treatment of some cancers, like breast cancer, is now established as a major therapeutic option (Dowsett, 1990). Nevertheless, despite the presence of receptors for steroid hormones in astroglial and neuronal cells (Toran-Allerand, 1978;Stumpf and O'Brien, 1987;Paoletti et al, 1990;Simerley, 1993), this approach has retained little attention in the treatment of brain tumors.…”

Formestane

“…[2,[33][34][35][36][37][38] Intramuscular formestane 50 mg/kg administered either daily or once every 2 weeks for up to 5 months caused tumour regression in approximately 90 to 100% of rats with chemically induced mammary tumours. [2,[33][34][35][36][37][38] Intramuscular formestane 50 mg/kg administered either daily or once every 2 weeks for up to 5 months caused tumour regression in approximately 90 to 100% of rats with chemically induced mammary tumours.…”

Induction of glioma cell death by 1,25 (OH)2 vitamin D3: Towards an endocrine therapy of brain tumors?

“…This knowledge gap, together with the absence of any curative treatment, has led to the development of other therapeutic approaches like immunotherapy (Merchant et al, 1992;Holladay et al, 1992;Trojan et al, 1993) and gene therapy (Culver et al, 1992). The endocrine treatment of some cancers, like breast cancer, is now established as a major therapeutic option (Dowsett, 1990). Nevertheless, despite the presence of receptors for steroid hormones in astroglial and neuronal cells (Toran-Allerand, 1978;Stumpf and O'Brien, 1987;Paoletti et al, 1990;Simerley, 1993), this approach has retained little attention in the treatment of brain tumors.…”

Formestane

“…[2,[33][34][35][36][37][38] Intramuscular formestane 50 mg/kg administered either daily or once every 2 weeks for up to 5 months caused tumour regression in approximately 90 to 100% of rats with chemically induced mammary tumours. [2,[33][34][35][36][37][38] Intramuscular formestane 50 mg/kg administered either daily or once every 2 weeks for up to 5 months caused tumour regression in approximately 90 to 100% of rats with chemically induced mammary tumours.…”

Induction of glioma cell death by 1,25 (OH)2 vitamin D3: Towards an endocrine therapy of brain tumors?

“…This knowledge gap, together with the absence of any curative treatment, has led to the development of other therapeutic approaches like immunotherapy (Merchant et al, 1992;Holladay et al, 1992;Trojan et al, 1993) and gene therapy (Culver et al, 1992). The endocrine treatment of some cancers, like breast cancer, is now established as a major therapeutic option (Dowsett, 1990). Nevertheless, despite the presence of receptors for steroid hormones in astroglial and neuronal cells (Toran-Allerand, 1978;Stumpf and O'Brien, 1987;Paoletti et al, 1990;Simerley, 1993), this approach has retained little attention in the treatment of brain tumors.…”